TerminatedPhase 3

L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)

Stopped: terminated

France44 participantsStarted 2000-07

Plain-language summary

Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive. The current study was designed to determine whether oral treatment with L-Arginine, a nitric oxide (NO) donor, would enhance birth weight and/or decrease neonatal morbidity in pregnancies with severe vascular intrauterine growth restriction (IUGR).

Who can participate

Age range18 Years – 55 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Multicenter randomized trial. * Patients with a singleton pregnancy with IUGR defined by fetal abdominal circumference less than or equal to the third percentile for gestational age, and abnormal uterine Doppler. Uterine Doppler was considered pathologic if Pourcelot's resistance index (S-D/S) was equal to or higher than 0.7, and/or if an obvious notch was present. If the placenta was not median, the side of the pathologic Doppler had to be on the same side as the placenta Exclusion Criteria: * Acute fetal distress * Non vascular and non severe IUGR (normal uterine doppler scans and/or abdominal circumference \> 3rd percentile) * Maternal immune disorder * IUGR from an infectious etiology * IUGR associated with fetal malformation, multifetal pregnancy, and preeclampsia upon inclusion

What they're measuring

The principal outcome is birth weight at delivery and neonatal morbidity (Crib Score)

Timeframe: 6 weeks

Trial details

NCT IDNCT00549575

SponsorNantes University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL